Viatris Additional Paid-in Capital 2012-2026 | VTRS
Viatris additional paid-in capital from 2012 to 2026. Additional paid-in capital can be defined as the excess over par value paid for common securities.
- Viatris additional paid-in capital for the quarter ending March 31, 2026 was $18.801B, a 0.64% decline year-over-year.
- Viatris additional paid-in capital for 2025 was $18.801B, a 0.64% decline from 2024.
- Viatris additional paid-in capital for 2024 was $18.922B, a 0.57% increase from 2023.
- Viatris additional paid-in capital for 2023 was $18.815B, a 0.91% increase from 2022.
|
Viatris Annual Additional Paid-in Capital (Millions of US $) |
|
|---|---|
| 2025 | $18,801 |
| 2024 | $18,922 |
| 2023 | $18,815 |
| 2022 | $18,646 |
| 2021 | $18,536 |
| 2020 | $18,439 |
| 2019 | $8,644 |
| 2018 | $8,591 |
| 2017 | $8,586 |
| 2016 | $8,499 |
| 2015 | $7,129 |
| 2014 | $4,213 |
| 2013 | $4,104 |
| 2012 | $3,987 |
| 2011 | $3,795 |
|
Viatris Quarterly Additional Paid-in Capital (Millions of US $) |
|
|---|---|
| 2025-12-31 | $18,801 |
| 2025-09-30 | $18,891 |
| 2025-06-30 | $18,998 |
| 2025-03-31 | $18,961 |
| 2024-12-31 | $18,922 |
| 2024-09-30 | $18,889 |
| 2024-06-30 | $18,853 |
| 2024-03-31 | $18,840 |
| 2023-12-31 | $18,815 |
| 2023-09-30 | $18,761 |
| 2023-06-30 | $18,719 |
| 2023-03-31 | $18,680 |
| 2022-12-31 | $18,646 |
| 2022-09-30 | $18,617 |
| 2022-06-30 | $18,586 |
| 2022-03-31 | $18,555 |
| 2021-12-31 | $18,536 |
| 2021-09-30 | $18,514 |
| 2021-06-30 | $18,490 |
| 2021-03-31 | $18,465 |
| 2020-12-31 | $18,439 |
| 2020-09-30 | $8,688 |
| 2020-06-30 | $8,673 |
| 2020-03-31 | $8,658 |
| 2019-12-31 | $8,644 |
| 2019-09-30 | $8,638 |
| 2019-06-30 | $8,617 |
| 2019-03-31 | $8,607 |
| 2018-12-31 | $8,591 |
| 2018-09-30 | $8,585 |
| 2018-06-30 | $8,613 |
| 2018-03-31 | $8,610 |
| 2017-12-31 | $8,586 |
| 2017-09-30 | $8,571 |
| 2017-06-30 | $8,545 |
| 2017-03-31 | $8,522 |
| 2016-12-31 | $8,499 |
| 2016-09-30 | $8,485 |
| 2016-06-30 | $7,179 |
| 2016-03-31 | $7,150 |
| 2015-12-31 | $7,129 |
| 2015-09-30 | $7,094 |
| 2015-06-30 | $7,075 |
| 2015-03-31 | $7,008 |
| 2014-12-31 | $4,213 |
| 2014-09-30 | $4,170 |
| 2014-06-30 | $4,149 |
| 2014-03-31 | $4,122 |
| 2013-12-31 | $4,104 |
| 2013-09-30 | $4,069 |
| 2013-06-30 | $4,045 |
| 2013-03-31 | $4,021 |
| 2012-12-31 | $3,987 |
| 2012-09-30 | $3,870 |
| 2012-06-30 | $3,835 |
| 2012-03-31 | $3,814 |
| 2011-12-31 | $3,795 |
| 2011-09-30 | $3,783 |
| 2011-06-30 | $3,919 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $17.911B | $14.300B |
| Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CVS Health (CVS) | United States | $129.251B | 14.33 |
| Danaher (DHR) | United States | $126.118B | 22.33 |
| Elevance Health (ELV) | United States | $85.740B | 12.83 |
| HCA Healthcare (HCA) | United States | $83.631B | 13.02 |
| Cencora (COR) | United States | $52.781B | 16.27 |
| Natera (NTRA) | United States | $32.768B | 0.00 |
| Labcorp Holdings (LH) | United States | $20.863B | 15.10 |
| DiDi Global (DIDIY) | China | $16.365B | 25.64 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $13.375B | 0.00 |
| BrightSpring Health Services (BTSG) | United States | $13.258B | 54.19 |
| Medpace Holdings (MEDP) | United States | $13.014B | 28.64 |
| Solventum (SOLV) | United States | $12.739B | 11.79 |
| Revvity (RVTY) | United States | $11.049B | 19.34 |
| ICON (ICLR) | Ireland | $10.775B | 12.49 |
| BioMerieux (BMXMF) | France | $9.232B | 0.00 |
| Charles River Laboratories (CRL) | United States | $8.745B | 18.16 |
| HealthEquity (HQY) | United States | $7.074B | 23.57 |
| Sonic Healthcare (SKHHY) | Australia | $6.895B | 0.00 |
| Avantor (AVTR) | United States | $6.384B | 11.00 |
| PACS (PACS) | United States | $5.978B | 24.21 |
| GETINGE (GNGBY) | Sweden | $5.438B | 17.36 |
| Bausch + Lomb (BLCO) | Canada | $5.331B | 22.97 |
| CochLear (CHEOY) | Australia | $5.195B | 0.00 |
| Caris Life Sciences,�Inc (CAI) | United States | $4.893B | 0.00 |
| Sotera Health (SHC) | United States | $4.489B | 19.92 |
| Alignment Healthcare (ALHC) | United States | $4.401B | 236.56 |
| Concentras Parent (CON) | United States | $3.646B | 19.78 |
| Organon (OGN) | United States | $3.519B | 4.27 |
| Establishment Labs Holdings (ESTA) | United States | $2.533B | 0.00 |
| Amplifon S.p.A (AMFPF) | Italy | $2.466B | 13.19 |
| Progyny (PGNY) | United States | $2.059B | 34.13 |
| Pediatrix Medical (MD) | United States | $1.932B | 11.59 |
| Surgery Partners (SGRY) | United States | $1.903B | 58.20 |
| Agilon Health (AGL) | United States | $1.887B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $1.732B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $1.704B | 0.00 |
| GeneDx Holdings (WGS) | United States | $1.645B | 65.20 |
| Teladoc Health (TDOC) | United States | $1.368B | 0.00 |
| Ardent Health (ARDT) | United States | $1.294B | 5.51 |
| CareDx (CDNA) | United States | $1.294B | 0.00 |
| InnovAge Holding (INNV) | United States | $1.250B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.240B | 0.00 |
| Omada Health (OMDA) | United States | $1.069B | 0.00 |
| Nutex Health (NUTX) | United States | $1.033B | 11.60 |
| GoodRx Holdings (GDRX) | United States | $0.880B | 16.06 |
| CryoPort (CYRX) | United States | $0.744B | 0.00 |
| Enhabit (EHAB) | United States | $0.709B | 25.89 |
| Strata Critical Medical (SRTA) | United States | $0.498B | 0.00 |
| Charming Medical (MCTA) | Hong Kong, SAR China | $0.497B | 0.00 |
| Oncology Institute (TOI) | United States | $0.495B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.389B | 4.74 |
| Shoulder Innovations (SI) | United States | $0.369B | 0.00 |
| Forward Industries (FWDI) | United States | $0.319B | 0.00 |
| SBC Medicals (SBC) | United States | $0.303B | 7.56 |
| LifeMD (LFMD) | United States | $0.208B | 0.00 |
| Embecta (EMBC) | United States | $0.180B | 1.17 |
| Biodesix (BDSX) | United States | $0.180B | 0.00 |
| So-Young (SY) | China | $0.159B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.100B | 0.00 |
| SkinHealth Systems (SKIN) | United States | $0.087B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.086B | 14.28 |
| Park Dental Partners (PARK) | United States | $0.082B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.072B | 0.00 |
| DocGo (DCGO) | United States | $0.053B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.028B | 0.00 |
| Lifeward (LFWD) | United States | $0.020B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.017B | 0.00 |
| Ainos (AIMD) | United States | $0.016B | 0.00 |
| OSR Holdings (OSRH) | United States | $0.013B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.013B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.012B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.012B | 0.00 |
| Pomdoctor - (POM) | China | $0.011B | 0.00 |
| XWELL (XWEL) | United States | $0.010B | 0.00 |
| Aclarion (ACON) | United States | $0.007B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.007B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.006B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.006B | 0.00 | |
| Intelligent Bio Solutions (INBS) | United States | $0.006B | 0.00 |
| ISpecimen (ISPC) | United States | $0.004B | 0.00 |
| Synergy CHC (SNYR) | United States | $0.003B | 0.00 |
| INVO Fertility (IVF) | United States | $0.002B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |